Formulation and statistical optimization of intravenous temozolomide-loaded PEGylated liposomes to treat glioblastoma multiforme by three-level factorial design

Vanza, Jigar; Jani, Parva; Pandya, Nilima; Tandel, Hemal

doi:10.1080/03639045.2017.1421661

Cited by 32 publications

(18 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Vanza et al encapsulated TMZ in a PEGylated liposome made of soybean phosphatidylcholine (PC), dipalmitoyl phosphatidylcholine (DPPC), dipalmitoyl phosphatidylcholine-sodium (DPPG), egg lecithin, cholesterol, and 1,2-distearoyl-phosphatidylethanolamine-methyl-polyethyleneglycol conjugate-2000 (Na + salt) [2]. The results revealed a prolonged release of TMZ from PEGylated liposomes up to 800 min, as compared with free TMZ, which was released in 90 min, according to in vitro studies.…”

Section: Stealth Liposomesmentioning

confidence: 99%

“…In 2016, 330,000 new patients were diagnosed, while the death toll from CNS tumors reached 227,000 [1]. GBM is the most aggressive form of brain cancer, is incurable and has an average survival rate of 12 months [2]. The main challenges raised by this disease are its high degree of genetic and phenotypic heterogeneity, the blood brain barrier, its increased resistance to therapies, and the existence of cancer stem cells [3,4].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Liposomal-Based Formulations: A Path from Basic Research to Temozolomide Delivery Inside Glioblastoma Tissue

et al. 2022

View full text Add to dashboard Cite

Glioblastoma (GBM) is a lethal brain cancer with a very difficult therapeutic approach and ultimately frustrating results. Currently, therapeutic success is mainly limited by the high degree of genetic and phenotypic heterogeneity, the blood brain barrier (BBB), as well as increased drug resistance. Temozolomide (TMZ), a monofunctional alkylating agent, is the first line chemotherapeutic drug for GBM treatment. Yet, the therapeutic efficacy of TMZ suffers from its inability to cross the BBB and very short half-life (~2 h), which requires high doses of this drug for a proper therapeutic effect. Encapsulation in a (nano)carrier is a promising strategy to effectively improve the therapeutic effect of TMZ against GBM. Although research on liposomes as carriers for therapeutic agents is still at an early stage, their integration in GBM treatment has a great potential to advance understanding and treating this disease. In this review, we provide a critical discussion on the preparation methods and physico-chemical properties of liposomes, with a particular emphasis on TMZ-liposomal formulations targeting GBM developed within the last decade. Furthermore, an overview on liposome-based formulations applied to translational oncology and clinical trials formulations in GBM treatment is provided. We emphasize that despite many years of intense research, more careful investigations are still needed to solve the main issues related to the manufacture of reproducible liposomal TMZ formulations for guaranteed translation to the market.

show abstract

Section: Stealth Liposomesmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Liposomal-Based Formulations: A Path from Basic Research to Temozolomide Delivery Inside Glioblastoma Tissue

et al. 2022

View full text Add to dashboard Cite

show abstract

“…These nanoparticles have been shown to reduce the systemic toxicity of chemotherapeutic agents, to improve their pharmacokinetics and enhance their selective accumulation in the tumor site. [46][47][48][49][50][51] Polymeric nanoparticles (PNPs) are considered to be the most promising alternative to lipid-based carriers for the delivery of chemotherapeutic agents to the brain. PNPs include poly-(alkyl cyanoacrylate) (PACA), poly-(l-glutamic acid) poly (lactide-co-glycolide, PLGA), polylactide (PLA), polyethyleneimine (PEI), N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer, poly(ethylene glycol) (PEG), dextran, and chitosan.…”

Section: Chemotherapeutic Deliverymentioning

confidence: 99%

Targeting Glioblastoma: Advances in Drug Delivery and Novel Therapeutic Approaches

Yeini

Ofek

Albeck

et al. 2020

Advanced Therapeutics

View full text Add to dashboard Cite

Glioblastoma (GB) is the most lethal type of primary tumor in the central nervous system. Current treatments include surgical resection followed by chemotherapy and radiotherapy. With this therapeutic regimen, the median survival is less than two years. However, these treatments do not much improve the overall survival of GB patients. GBs are highly angiogenic and invasive tumors and often acquire resistance to therapy. The invasive nature of the disease limits the ability to achieve complete resection of the tumor and the majority of GB patients will experience disease relapse. Moreover, GB is highly heterogeneous, harboring different mutations and presenting different phenotypes. As the brain is considered to be an immune‐privileged tissue, GB is defined as a cold tumor for which current immunotherapies have not yet been demonstrated to improve survival. On top of these challenges, the blood brain barrier (BBB) restricts the uptake of drugs by the brain, thus limiting the therapeutic options. Therefore, enormous efforts are being dedicated to the development of novel nanomedicines, which will be able to cross the BBB and specifically target the cancer cells. Here, the current achievements in drug delivery and novel therapeutic approaches for GB therapy are discussed.

show abstract

“…It has been demonstrated that the currently limited efficacy of convection-enhanced delivery (CED) could be enhanced by a liposomal formulation, thus achieving enhanced TMZ localization to the tumor site with minimal toxicity. On the other hand, a novel approach has been described for treating GBM by CED of (PEGylated) liposomes containing TMZ, the known chemotherapeutic agent (Vanza et al, 2018;Lin et al, 2018.;Nordling-David et al, 2017). However, to our knowledge no magnetic targeting of temozolomide is ever presented in the literature.…”

Section: Surface Coating Of Magnetic Nanoparticlesmentioning

confidence: 99%

Targeting of temozolomide using magnetic nanobeads: an in vitro study

Gurten

Yenigül

Sezer

et al. 2020

Braz. J. Pharm. Sci.

View full text Add to dashboard Cite

Temozolomide, a chemotherapeutic drug that is often administered for the treatment of brain cancer has severe side effects and a poor aqueous solubility. In order to decrease the detrimental effect of the drug over healthy cells, a novel drug delivery vehicle was developed where the therapeutic drug was encapsulated within the hydrophobic cavities of b-CD modified magnetite nanoparticles, which are embedded in chitosan nanobeads prepared by salt addition. In-vitro studies have shown that the magnetic properties of the novel delivery vehicle are adequate for targeted drug delivery applications under an external magnetic field. Additionally, an increase in the amount of chitosan was shown to exhibit a strong shielding effect over the magnetic properties of the delivery vehicle, which lead to deterioration of the amount of captured drug at the targeted area, suggesting a delicate balance between the amounts of constituents composing the drug delivery vehicle.

show abstract

Formulation and statistical optimization of intravenous temozolomide-loaded PEGylated liposomes to treat glioblastoma multiforme by three-level factorial design

Cited by 32 publications

References 43 publications

Liposomal-Based Formulations: A Path from Basic Research to Temozolomide Delivery Inside Glioblastoma Tissue

Liposomal-Based Formulations: A Path from Basic Research to Temozolomide Delivery Inside Glioblastoma Tissue

Targeting Glioblastoma: Advances in Drug Delivery and Novel Therapeutic Approaches

Targeting of temozolomide using magnetic nanobeads: an in vitro study

Contact Info

Product

Resources

About